Dynavax Technologies Corp (NASDAQ:DVAX)

23.58
Delayed Data
As of Apr 17
 -0.58 / -2.40%
Today’s Change
12.50
Today|||52-Week Range
26.89
+39.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$681.8M

Company Description

Dynavax Technologies Corp. is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Its lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. The company's other products under pipeline are DV1179 (TLR Inhibitor for Lupus) and AZD1419 (Asthma Therapy). Dynavax Technologies was founded by Lawrence M. Lichtenstein, Dennis A. Carson and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Contact Information

Dynavax Technologies Corp.
2929 7th Street
Berkeley California 94710-2753
P:(510) 848-5100
Investor Relations:

Employees

Shareholders

Mutual fund holders43.78%
Other institutional28.12%
Individual stakeholders0.21%

Top Executives

Eddie J. GrayChief Executive Officer & Director
David F. NovackSenior Vice President-Operations & Quality
Michael S. OstrachCFO, Secretary, Chief Business Officer & VP
Robert L. CoffmanChief Scientific Officer & Senior Vice President
Robert JanssenChief Medical Officer & VP-Regulatory Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account